The firm is now launching the test in Europe, supported by results from a multicenter prospective study showing high sensitivity in detecting bladder cancer.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
The company had encouraging results for its breast cancer tests and provided an update on the development of its bladder cancer test.
The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.
The urine-based test combines massively parallel sequencing with proprietary error-reducing technology developed at Johns Hopkins.
The University of Minnesota's Shilpa Gupta will work with Biocept on a study aimed at providing clinical support for the use of the firm's PD-L1 and AR tests.
In the second half of the year, the firm plans to introduce a urine-based bladder cancer test and achieve sales growth between 30 and 50 percent.
The company plans to launch its first bladder cancer test in the second half of the year, and is in the early stages of validating a third test for prostate cancer.
The test may help identify patients most likely to respond to Roche's new metastatic urothelial cancer drug Tecentriq, the FDA said.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.